Workshop on response criteria and evaluation of the stable disease category in carcinoma of the prostate, breast, and large bowel.
A multidisciplinary conference reviewed the clinical response criteria for the evaluation of stable disease category in a number of solid tumors, including prostate, breast, and large bowel cancer. Some similarities between the situation in hormonally responsive tumors, such as breast and prostate, were elucidated. With regard to bowel cancer, the principal site of metastases currently under evaluation is the liver site. Although ultrasound appears to be useful for following such lesions, it has also been shown that direct suturotomy is necessary. With regard to the overall situation involving the stable category, it was pointed out that, after due deliberation, for some solid tumors stable category may well be most important in that drugs that achieved this status may be otherwise discarded because of unprecise measurements. Greater accuracy in measurement and availability with current external diagnostic techniques were acknowledged and their applicability to certain situations was enumerated. It was also felt that there is a place, when documented, for the stable category, particularly prostate cancer. The reasons for this are discussed.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000556:secondary; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D014463:Ultrasonography
D000970:Antineoplastic Agents